Tvardi Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $9.10M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | Before market open | – | $-0.69 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 8, 2026 | Before market open | – | $-0.73 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | During market hours | – | $-0.78 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | – | $-0.59 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | During market hours | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | During market hours | $2.10M | $-0.56 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 4, 2024 | During market hours | $3.00M | $-0.59 | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | During market hours | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 7, 2023 | During market hours | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 15, 2023 | During market hours | – | – | – |
Press releases
Announcements Tvardi Therapeutics filed with the SEC
Tvardi Therapeutics Announces Second Quarter
Results of operations · EX-99.1 to Form 8-K
Tvardi Therapeutics Selects Ulcerative Colitis
Regulation FD disclosure · EX-99.1 to Form 8-K
TTI - 101 in HCC
Regulation FD disclosure · EX-99.2 to Form 8-K
Tvardi Therapeutics’ TTI-109 Phase 1 Study
Regulation FD disclosure · EX-99.1 to Form 8-K
TTI - 101 in HCC
Regulation FD disclosure · EX-99.2 to Form 8-K
Tvardi Therapeutics Announces First Quarter
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
contained in this presentation, including statements about our expectations regarding the potential benefits, activity, effectiveness, and safety of our product candidates,
Regulation FD disclosure · EX-99.1 to Form 8-K
contained in this presentation, including statements about our expectations regarding the potential benefits, activity, effec tiveness, and safety of our product candidates,
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Third Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Therapeutics Provides Update on Preliminary Data from
Other events · EX-99.1 to Form 8-K
Tvardi Therapeutics Announces Second Quarter
Results of operations · EX-99.1 to Form 8-K
Tvardi Therapeutics Announces Completion of
Regulation FD disclosure · EX-99.1 to Form 8-K
Quarter 2025 Results and Provides Business Update
Results of operations · Auditor change · EX-99.1 to Form 8-K
Tvardi Therapeutics Announces Closing of Merger
Material agreement · Acquisition or disposition completed · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cara Therapeutics Announces 1-for-3 Reverse
Material agreement · Acquisition or disposition completed · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
This presentation and any accompanying oral commentary have been prepared by Tvardi Therapeutics, Inc. (“Tvardi”) for informational purposes only and not for any other purpose.
Regulation FD disclosure · EX-99.1 to Form 8-K
Report of independent registered public accounting firm
Shareholder vote results · Other events · EX-99.1 to Form 8-K
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Shareholder vote results · Other events · EX-99.2 to Form 8-K
terms included below shall have the same meaning as terms defined and included in the Registration Statement on Form S-4 (File No. 333-283900),
Shareholder vote results · Other events · EX-99.3 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Cara Therapeutics and Tvardi Therapeutics Announce
Material agreement · Executive or director change · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Executive or director change · Other events · EX-99.2 to Form 8-K
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Announces Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cara Therapeutics Announces Outcome from Dose-Finding
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Cara Therapeutics Reports Third Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Cara Therapeutics Announces up to $40.0 Million
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Cara Therapeutics Reports Second Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Appoints Helen M. Boudreau to
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
J.P. Morgan Healthcare Conference January 9, 2023
Regulation FD disclosure · EX-99.1 to Form 8-K